We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

15 hedge funds and large institutions have $85.3M invested in Tonix Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

64% more capital invested

Capital invested by funds: $52M → $85.3M (+$33.3M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

25% more funds holding

Funds holding: 12 → 15 (+3)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.3M
2
State Street
State Street
Massachusetts
+$5.88M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.94M
4
Norges Bank
Norges Bank
Norway
+$2.94M
5
Northern Trust
Northern Trust
Illinois
+$2.94M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.47M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.01M
3
Citadel Advisors
Citadel Advisors
Florida
-$776K
4
ECM
ExodusPoint Capital Management
New York
-$735K
5
Millennium Management
Millennium Management
New York
-$735K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$29.4M +$21.3M +29 +242%
Vanguard Group
2
Vanguard Group
Pennsylvania
$17.5M +$1.47M +2 +9%
Renaissance Technologies
3
Renaissance Technologies
New York
$8M -$1.47M -2 -15%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$6.13M +$2.94M +4 +80%
State Street
5
State Street
Massachusetts
$5.66M +$5.88M +8 New
Northern Trust
6
Northern Trust
Illinois
$3.45M +$2.94M +4 +400%
Norges Bank
7
Norges Bank
Norway
$3.06M +$2.94M +4 New
N
8
Nuveen
North Carolina
$1.94M +$2.21M +3 New
Bank of New York Mellon
9
Bank of New York Mellon
New York
$1.07M +$1.47M +2 New
Millennium Management
10
Millennium Management
New York
$922K -$735K -1 -50%
Charles Schwab
11
Charles Schwab
California
$909K +$735K +1 New
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$834K +$735K +1 New
GCP
13
GSA Capital Partners
United Kingdom
$751K – – –
California State Teachers Retirement System (CalSTRS)
14
California State Teachers Retirement System (CalSTRS)
California
$500K +$735K +1 New
RhumbLine Advisers
15
RhumbLine Advisers
Massachusetts
$358K +$735K +1 New
VF
16
Virtu Financial
New York
$327K – – –
Morgan Stanley
17
Morgan Stanley
New York
$314K – – –
New York State Common Retirement Fund
18
New York State Common Retirement Fund
New York
$311K – – –
AQR Capital Management
19
AQR Capital Management
Connecticut
$268K – – –
ECM
20
ExodusPoint Capital Management
New York
$239K -$735K -1 Closed
BCM
21
Bridgeway Capital Management
Texas
$238K – – –
AllianceBernstein
22
AllianceBernstein
Tennessee
$224K – – –
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$218K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$215K – – –
First Trust Advisors
25
First Trust Advisors
Illinois
$192K – – –
1
2 3 4

TNXP Hedge Fund Activity: Q2 2021 in Review

15 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q2 2021, worth a combined $85.3M — up 64% from $52M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TNXP positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was Renaissance Technologies, cutting an estimated $1.47M.

  • 15 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q2 2021, up from 12 in Q1 2021.
  • Funds reported $85.3M of Tonix Pharmaceuticals stock for Q2 2021, up 64% quarter-over-quarter.
  • 8 funds opened new Tonix Pharmaceuticals positions in Q2 2021 and 5 closed out, a net change of +3 holders.
  • The largest Tonix Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $21.3M added.
  • The largest Tonix Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $1.47M sold.

Based on aggregated 13F filings for Q2 2021.